ArticleProbiotics and antimicrobial proteins2026
Designing a Potent, Low-Toxicity Antimicrobial Peptide Inspired by Scorpion Peptides: Optimizing Expression and Activity.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- α-Helical peptides: design strategies and recent advances in biomedical applications.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scorpion venom contains diverse antimicrobial peptides (AMPs) characterized by conserved structures across different species. The potency and small size of these AMPs have facilitated their production and application. However, natural AMPs often lack the necessary potency for clinical use due to instability and weak effect on a broad range of microbes, such as Gram-negative bacteria. To overcome the limited potency of scorpion AMPs, we designed Mu-17, a novel peptide based on a leucine zipper motif derived from the conserved structure of scorpion AMPs. Mu-17 consists of 17 residues, LFRLIPSLIKRLISAFK, that form an amphipathic alpha-helix structure. The gene encoding Mu-17 was constructed and cloned into a bacterial expression system. We optimized bacterial transformation and expression conditions to reduce the toxicity of Mu-17, a common challenge in the production of recombinant AMPs. The purified recombinant Mu-17 exhibited broad-spectrum antimicrobial activity against Gram-positive bacteria (Bacillus sp. and Staphylococcus sp.), Gram-negative bacteria (Escherichia coli), and the yeast Candida albicans, with minimum inhibitory concentrations (MICs) ranging from 1.5 to 5 µM. Additionally, Mu-17 inhibited breast cancer cell proliferation with an IC50 value of 13 µM. Mu-17 exhibited remarkably low hemolytic activity, at 18% for a 100 µM concentration, significantly improving over many potent AMPs with known toxicity issues. The antimicrobial activity of Mu-17 likely occurs through membrane interaction. Our findings demonstrate that bio-inspired design based on scorpion AMP leucine zipper-like motif can yield novel peptides with potent antimicrobial and anticancer activity along with reduced toxicity, positioning Mu-17 as a promising lead for therapeutic development.
Indexed as
Identifiers
40593394What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.